(Q33376623)

26 July 2017

title

Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC). (English)

1 reference

26 July 2017

1 reference

1 reference

Joseph G Kattan

1

1 reference

26 July 2017

Fady S Farhat

2

1 reference

26 July 2017

Georges Y Chahine

3

1 reference

26 July 2017

Fady L Nasr

4

1 reference

26 July 2017

Walid T Moukadem

5

1 reference

26 July 2017

Fariha C Younes

6

1 reference

26 July 2017

Nadine J Yazbeck

7

1 reference

26 July 2017

Marwan G Ghosn

8

1 reference

26 July 2017

Cancer Research Group

9

1 reference

26 July 2017

publication date

6 September 2007

1 reference

Investigational New Drugs

26 July 2017

published in

1 reference

26 July 2017

volume

26

1 reference

26 July 2017

issue

1

1 reference

26 July 2017

page(s)

75-79

1 reference

Future therapies in hormone-refractory prostate cancer

26 July 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10637-007-9074-3

Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma

21 January 2018

1 reference

12 December 2020

Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer

1 reference

12 December 2020

Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.

1 reference

12 December 2020

A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer

1 reference

12 December 2020

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

12 December 2020

Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer

1 reference

12 December 2020

One-sample multiple testing procedure for phase II clinical trials

1 reference

12 December 2020

Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer

1 reference

12 December 2020

Erythema multiforme major following docetaxel

1 reference

12 December 2020

Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma

1 reference

12 December 2020

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

12 December 2020

Weekly docetaxel and zoledronic acid every 4 weeks in hormone-refractory prostate cancer patients

1 reference

12 December 2020

Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate

1 reference

12 December 2020

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

12 December 2020

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

1 reference

12 December 2020

Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response

1 reference

12 December 2020

The McGill Pain Questionnaire: Major properties and scoring methods

1 reference

12 December 2020

Practical aspects of weekly docetaxel administration schedules

1 reference

12 December 2020

Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer

1 reference

12 December 2020

10.1007/S10637-007-9074-3

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

1046462340

0 references

1 reference